This case is notable as it appears to be the first reported instance of combining an anti-VEGFR agent (bevacizumab) and an immune checkpoint inhibitor (atezolizumab) with high-dose vitamin C in an unresectable HCC patient. This evidence concerns the gene KDR and hepatocellular carcinoma.